Recently, mass cytometry and single-cell RNA sequencing of patient tumor specimens from various ICI-responding and non-responding cancers, such as GBM, revealed enrichment of CD73-high macrophages in GBM, which persist through anti-PD-1 treatment and limit ICI efficacy by inhibiting T cell infiltration [67]. Here, PDCD1 is linked to cancer.